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Despite advances in surgical technique and radiation therapy, the
prognosis for malignant glioma patients remains dismal, with a 
2-year survival rate of less than 20% (Prados and Levin, 2000).
Among the brain tumours, malignant gliomas represent 13–22%
and are the leading cause of death from cancer in persons 15 to 34
years of age (Harbaugh and Black, 1998). Brain tumours are the
second leading cause of cancer death in children in the United
States, and their incidence is on the rise (Schmidt, 1998).
Presently, the medical treatment of cancer is based on surgery and
radiation therapy which may or may not be followed by
chemotherapy (Shapiro, 1999; Yung et al, 2000). However, invas-
iveness combined with multidrug resistance protects most malig-
nant gliomas from direct chemical, radiological or surgical assault
(Harbaugh and Black, 1998). Since malignant brain tumours
remain as lethal today as they were in the 1970s, new therapeutic
approaches are urgently needed (Davis et al, 1999; Fathallah-
Shaykh, 1999). 
The glycosphingolipids (GSLs) comprise the gangliosides and
the neutral GSLs and are anchored in the outer surface of plasma
membranes through a lipophilic ceramide tail (Hakomori, 1996;
Bai and Seyfried, 1997). Gangliosides differ from the neutral
GSLs in having at least one sialic acid molecule attached to the
oligosaccharide head group. N-acetylneuraminic acid (NeuAc)
and N-glycolylneuraminic acid are the major sialic acid species
present in mouse tissues. Chemotherapy through slowing GSL
synthesis has been proposed based on evidence that GSLs may
modulate tumour growth, metastasis, immunity and multidrug
resistance (Chang et al, 1997; Liu et al, 1999; Radin, 1999).
Defects in GSL biosynthesis are found in most human cancers and
may underlie the invasive and malignant properties of brain
tumours (Merzak et al, 1995; Hakomori, 1996; Berra et al, 1997).
GSLs can modulate the function of growth factor receptors and
have recently been implicated as modulators of brain tumour
angiogenesis and cell adhesion (Hakomori, 1996; Alessandri et al,
1997; Bai and Seyfried, 1997; Manfredi et al, 1999; Zeng et al,
2000). GSLs newly synthesized and shed by tumours can compet-
itively bind to interleukin-2 (IL-2) receptors on T cells, hindering
the proliferative response required for immunological rejection
(Chang et al, 1997). Taken together, these findings suggest that the
modification of GSL biosynthesis and expression could be effect-
ive in brain tumour therapy. 
Mammalian GSLs are synthesized by the stepwise addition of
sugar residues to the oligosaccharide head group. This is accom-
plished through the action of a Golgi-bound multi-glycosyltrans-
ferase system, where the GSL product of one transferase serves as
the substrate for another transferase (Sandhoff and van Echten,
1994; Seyfried et al, 1994). The small imino sugar, NB-DNJ,
inhibits the ceramide-specific glucosyltransferase (GlcT-1) that
catalyses the first step in GSL biosynthesis (Platt et al, 1994)
(Figure 1). Since GlcCer is the common metabolic precursor for
the synthesis of most gangliosides and neutral glycolipids, 
NB-DNJ treatment significantly reduces the content of all 
GSLs containing the GlcCer core structure (Platt et al, 1994). 
NB-DNJ is a derivative of the naturally occurring plant and 
microbial compound deoxynojirimycin (DNJ), and is water
soluble in contrast to other, highly hydrophobic inhibitors of GSL
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tered to adult mice in the diet without toxicity. Dietary administra-
tion of NB-DNJ prevents ganglioside GM2 accumulation in the
brains of mice with Tay Sachs and Sandhoff diseases and depletes
GSLs in metabolically active tissues of adult mice (Platt et al,
1994, 1997a, 1997b; Platt and Butters, 1995; Jeyakumar et al,
1999). NB-DNJ is therefore ideally suited as a pharmacological
agent for targeting GSL biosynthesis in vivo. 
NB-DNJ was used previously in clinical trials for Human
Immunodeficiency Virus (HIV) infection and is currently used in
clinical trials for the lipid storage disorder Gaucher’s disease (Fischl
et al, 1994; Cox et al, 2000). In this study, we have investigated for
the first time the influence of NB-DNJ on the growth and ganglio-
side content of two 20-methylcholanthrene (20 MC)-induced mouse
brain tumours, EPEN and CT-2A. The 20-MC-induced murine brain
tumours share a number of morphological, physiological, and
histological features with malignant brain tumours in humans
(Zimmerman, 1982; Seyfried et al, 1992; Seyfried, 2001). Our
present results demonstrate that NB-DNJ inhibits the growth and
ganglioside content of both the EPEN and the CT-2A experimental
brain tumours. These findings suggest that NB-DNJ may have clin-
ical efficacy in treating malignant brain cancer in humans. A prelim-
inary report of these findings has appeared (Ranes et al, 2000). 
MATERIALS AND METHODS 
Mice 
The C57BL/6 (B6) strain was obtained from the Jackson
Laboratory (Bar Harbor, ME). All B6 mice used in this study were
propagated in the animal room of the Biology Department, Boston
College, using animal husbandry conditions described previously
(Flavin et al, 1991). Age- and sex-matched (6–8 week-old male)
B6 mice were used as tumour recipients. All animal use proce-
dures were in accordance with the NIH Guide for the Care and Use
of Laboratory Animals and were approved by the Institutional
Animal Care Committee. 
Experimental mouse brain tumours 
Both EPEN and CT-2A experimental mouse brain tumours were
used for these studies. The EPEN tumour was originally produced
through implantation of 20-MC into the cerebral ventricle of a B6
mouse and had histological characteristics of an ependymoblas-
toma (Rubin, 1968). The CT-2A tumour was generated in our labor-
atory and arose in a B6 mouse 450 days after 20-MC implantation
into the cerebral cortex as previously described (Seyfried et al,
1992). Histologically, the CT-2A brain tumour was broadly 
classified as a poorly differentiated highly malignant anaplastic
astrocytoma. The EPEN tumour grows as a firm, cohesive,
nonhaemorrhagic mass in vivo and as cell islands in vitro, while the
CT-2A tumour grows as a soft, noncohesive, haemorrhagic mass in
vivo and as a fusiform monolayer in vitro (Seyfried et al, 1992).
Also, the growth rate is significantly greater for the CT-2A tumour
than for the EPEN tumour (Cotterchio and Seyfried, 1993). 
N-butyldeoxynojirimycin 
NB-DNJ (OGT918; 219.3, MW) was obtained as a gift from
Searle/Monsanto, St Louis, MO, and Oxford GlycoSciences,
Abigdon, UK. 
Cell culture and NB-DNJ treatment 
Approximately 2 ´ 103 EPEN or CT-2A tumour cells were seeded
in wells of a 24-well plate and cultured for 24 h in a humidified
atmosphere of 95% air and 5% CO2 at 37˚C in Dulbecco’s modi-
fied Eagle medium (DMEM) supplemented with 10% heat-
inactivated fetal bovine serum (FBS). Cells were cultured for an
additional 8 days in the presence or absence of 200 mM NB-DNJ.
A Coulter counter was used for cell counts of the control and
treated cells, and the trypan blue exclusion procedure was used to
assess the viability of tumour cells following NB-DNJ treatment
(Kemp, 1968). The number of dead cells that incorporated trypan
blue was counted using a haemacytometer. 
Subcutaneous and intracerebral tumour implantation 
An EPEN or CT-2A flank-grown tumour was removed from a B6
mouse and was rinsed and diced in cold phosphate-buffered saline
(PBS) at pH 7.4. The right flanks of recipient mice were shaved in
order to facilitate tumour inoculation, detection, and growth assess-
ment. Mice were anaesthetized with metofane (Methoxyflurane,
Mallinckrodt Veterinary Inc, Mundelein, IL), and the tumour was
implanted by the s.c. injection of 0.1 ml of minced tumour tissue
suspended in 0.2 ml PBS by use of a 1 cc tuberculin syringe and
18-gauge needle. The inoculated mice were monitored daily for
nodule formation. Tumours were implanted i.c. as previously
described (Seyfried et al, 1987). Mice were anaesthetized with
metofane, and their heads were shaved and then swabbed with
70% ethyl alcohol under sterile conditions. A midline incision was
made on the posterior aspect of the head and the periosteum was
swept laterally to expose the sagittal, coronal and lamboidal
sutures of the skull. A 1 mm burr hole was made, using an electric
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Figure 1 Influence of N B-DNJ on ganglioside biosynthesis. NB-DNJ
inhibits the ceramide-specific glucosyltransferase (GlcT) that catalyses the
first committed step in GSL biosynthesis. GlcCer, glucosylceramide; LacCer,
lactosylceramide; GalCer, galactosylceramide; GalCer-SO3, GalCer sulfate;
GlcT, glucosyltransferase drill, over the right parietal region behind the coronal suture and
lateral to the sagittal suture. A 1 mm3 tumour fragment was then
implanted into the right cerebral hemisphere of each anaesthetized
recipient B6 mouse using a trocar. The skin edges were immedi-
ately approximated using sterile surgical forceps and fused using
collodion (JT Baker, Inc, Phillipsburg, NJ). The animals recovered
spontaneously and were monitored and returned to their cages
when fully active. 
In vivo NB-DNJ treatment and tumour growth
assessment 
B6 mice bearing s.c. or i.c. tumors were randomized into either
control or treated groups and were housed 2 per cage. NB-DNJ
was administered in the diet as previously described (Platt et al,
1997a, 1997b). Mice in the control group received ground mouse
chow (Agway Prolab Rat/Mouse/Hamster 3000, PMI Feeds, Inc,
St Louis, MO). Mice in the treated group received ground mouse
chow containing NB-DNJ (2400 mg NB-DNJ kg body weight–1
day–1). Previous studies showed that this dietary dosage of NB-
DNJ reduces GSL content in liver and lymphoid organs by
50–70% and is well tolerated in B6 mice over a 2-week treatment
period (Platt et al, 1997b). The diet and compound (both as dry
solids) were mixed thoroughly before use, stored in an airtight
container at room temperature, and were used within 7 days of
mixing. Both control and NB-DNJ-containing diets were provided
ad libitum and were administered in glass vials that were fixed to
the cage bottom. Water was also provided ad libitum. 
Tumours grown s.c. were measured with calipers by the method
of Looney as previously described (Cotterchio and Seyfried, 1993).
Tumour volume was calculated by the formula for the approxima-
tion of the volume of a spheroid as Volume = 1/2 (Length ´ Width
´ Height). Tumour volume was measured every other day
throughout the treatment period. Since EPEN tumour growth rate is
slower than that of the CT-2A tumour, it took longer for the EPEN
tumour to reach a measurable size (30–40 mm3). Consequently,
NB-DNJ treatment of the EPEN or CT-2A tumours grown s.c. was
initiated on day 14 or on day 6 post-inoculation, respectively.
Treatment of the EPEN or CT-2A tumours was terminated on day
28 or on day 14 post-inoculation, respectively, when the control s.c.
tumours reached an approximate mean volume of 1000 mm3. 
NB-DNJ treatment was initiated 6 days after i.c. implantation for
both the EPEN and the CT-2A tumours. This ensured vigorous
tumour growth at the initiation of drug treatment. Unlike s.c. tumour
growth, cranium size constrains i.c. tumour growth. Consequently,
NB-DNJ treatment was terminated on day 15 post-implantation for
both tumours. In addition to tumour volume measurements, mouse
body weights were measured to the nearest 0.1 g and behavioural
activity (ambulation and grooming) was monitored. At the termina-
tion of drug treatment, all mice were sacrificed by cervical disloca-
tion and tumour, brain, liver and spleen tissue was collected, frozen
and then lyophilized. In an independent study, healthy mice were
treated with NB-DNJ (2400 mg kg–1 d–1) for 9 days to measure
serum and tissue NB-DNJ content. 
Analysis of gangliosides 
Gangliosides were isolated and purified from lyophilized tumour,
brain and liver tissue by our previously described methods (Seyfried
et al, 1978; Seyfried et al, 1987; El-Abbadi and Seyfried, 1994).
Briefly, total lipids were extracted in chloroform:methanol
(1:1, v/v). The Folch procedure was used to partition gangliosides
into the upper aqueous phase (Folch et al 1957). The upper phase
was converted to a chloroform:methanol:water ratio of 30:60:8
(v/v/v) for ion exchange chromatography (Seyfried et al, 1978).
Samples were then applied to a DEAE-Sephadex A-25 (Pharmacia
Biotech) column (acetate form) and non-acidic glycolipids were
eluted by washing with chloroform:methanol: water (30:60:8,
v/v/v). The gangliosides were then eluted from the column with
chloroform:methanol:0.8 M sodium acetate (30:60:8, v/v/v).
Residual phosphatides and ganglioside inner esters were removed
by a mild base treatment in 0.1 N sodium hydroxide at 37˚ C for 1.5
h. C18 Bond Elut columns (Varian) were used to remove salts and
base from ganglioside fractions. Quantification of N-acetylneu-
raminic acid (NeuAc) and 
N-glycolylneuraminic acid (NeuGc) was determined using a gas-
liquid chromatography procedure (Yu and Ledeen, 1970). The resor-
cinol reaction was also used to analyse ganglioside sialic acid
concentration in mouse brains as previously described (Seyfried
et al, 1978). Sialic acid concentration was expressed as mg 100 mg
dry weight–1. The distribution of tumour gangliosides was examined
using high performance thin-layer chromatography (HPTLC) as we
previously described (Cotterchio and Seyfried, 1993). Ganglioside
sialic acid was visualized on the HPTLC by the resorcinol-
hydrochloric acid spray (Svennerholm, 1957). 
Detection of NB-DNJ in serum and tissue of healthy
mice 
Serum and tissue NB-DNJ levels were quantified as previously
described (Andersson et al, 2000). Healthy 6–8 week-old-male B6
mice were treated for 9 days with NB-DNJ at 2400 mg kg–1 d–1.
Mice were sacrificed by carbon dioxide inhalation. Serum was
collected and stored at –20˚C. Brain and liver tissue was collected
and stored at –80˚C. Serum and supernatant of liver homogenate
(130 mg ml–1 in 10% methanol) were centrifuged 3 times through a
Millipore Ultrafree filter, after an internal standard (N-3-methyl-
butyl-DNJ) had been added to the samples. The pooled filtrates
were purified on a hydrochloric acid-preconditioned SCX column,
eluted with 1% ammonia in methanol, dried down, and resus-
pended in water. The samples were further purified on a C18
column (methanol preconditioning, water wash, and methanol
elution), and then quantified by HPLC (Dionex CS10 hpcec chro-
matography, isocratic elution with 50 mM sodium sulphate and
5% acetonitrile, pulsed amperometric detector). 
Histological examination 
Control and NB-DNJ-treated brains bearing the EPEN or the 
CT-2A tumours were dissected and fixed in formalin for 24 hours.
Specimens were embedded in paraffin and sectioned at 5 mm
thickness. For routine histological examination of tumour
morphology, the EPEN and the CT-2A tumour sections were
stained with haematoxylin-eosin (H&E) and examined by light
microscopy (Zeiss, West Germany). 
RESULTS 
Influence of NB-DNJ on in vitro EPEN and CT-2A cell
growth 
NB-DNJ (200 mM) significantly reduced the number of EPEN
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untreated cells after 8 days of treatment (Figure 2). NB-DNJ was
not cytotoxic since the percentage of trypan blue positive cells
(2–3%) was similar in both the control and treated flasks for both
tumour lines. These data indicate that NB-DNJ inhibited EPEN
and CT-2A cell proliferation without enhancing cytotoxicity. 
Influence of NB-DNJ on the EPEN and the CT-2A
tumour growth in vivo 
Based on the anti-proliferative effect of NB-DNJ on EPEN and CT-
2A tumour cells in vitro, we examined the effect of NB-DNJ on the
growth of both brain tumours in vivo. NB-DNJ (2400 mg kg–1 day–1)
significantly reduced both s.c. and i.c. growth of the EPEN and the
CT-2A tumours (Figures 3 and 4). The inhibitory effect of NB-DNJ
treatment on s.c. growth was apparent for both tumours by the
fourth or sixth day of treatment. By the end of treatment, the EPEN
and the CT-2A tumour volumes were reduced by 55% and 72%,
respectively, compared to tumours in the untreated control mice
(Figure 3). The greater inhibitory effect of NB-DNJ on the CT-2A
tumours than on the EPEN tumours may result from the faster
growth rate of the CT-2A tumours compared to the EPEN tumours. 
Total tumour dry weight was used to determine i.c. growth at the
end of the treatment period. Dry weight provides a more accurate
assessment of tumour growth than wet weight because it elimin-
ates variability due to differences in tissue water content associ-
ated with oedema. The dry weights of the NB-DNJ-treated EPEN
and CT-2A tumours were reduced by 71% and 55%, respectively,
compared to tumours in the untreated control mice (Figure 4). The
greater inhibitory effect of NB-DNJ on the EPEN tumours than on
the CT-2A tumours may result from the smaller size of the EPEN
than the CT-2A tumour at the initiation of drug treatment (day 6).
Taken together, these findings indicate that NB-DNJ effectively
inhibits the growth of the EPEN and the CT-2A tumours in both
subcutaneous and intracerebral environments. 
Influence of NB-DNJ on tumour, liver and brain
ganglioside content 
Since  NB-DNJ is a known inhibitor of GSL biosynthesis, we
1110 MK Ranes et al
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Figure 2 Influence of NB-DNJ on the in vitro growth rate of EPEN and
CT-2A experimental mouse brain tumour cells. Values are expressed as the
means ± SEM of 3 independent experiments for each cell line. The asterisks
indicate that cell counts were significantly lower in the NB-DNJ-treated flasks
than in the control flasks at the P < 0.01 level (two-tailed t-test) 
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Figure 3 Influence of NB-DNJ on the subcutaneous growth rate of EPEN
and CT-2A experimental mouse brain tumours. Day 0 represents the
beginning of tumour volume measurement, when tumours were
approximately 30–40 mm3. The values for each tumour (EPEN control, n = 4;
EPEN + NB-DNJ, n = 4; CT-2A control, n = 7; CT-2A + NB-DNJ, n = 7) are
expressed as means ± SEM. The asterisks indicate that NB-DNJ-treated
tumour volumes were significantly lower than control tumour volumes at the
P < 0.01 level (two-tailed t-test) 
60
50
40
30
20
10
0
EPEN CT-2A
Control
NB-DNJ
(2400 mg / kg / d)
T
u
m
o
u
r
 
d
r
y
 
w
e
i
g
h
t
 
(
m
g
)
*
*
Figure 4 Influence of NB-DNJ on the intracerebral growth of EPEN and
CT-2A experimental mouse brain tumours. Tumour dry weights (EPEN
control, n = 4; EPEN + NB-DNJ, n = 7; CT-2A control, n = 8; CT-2A + NB-
DNJ, n = 8) are expressed as the means ± SEM. The asterisks indicate that 
NB-DNJ-treated tumour dry weights were significantly lower than control
tumour dry weights at the P < 0.01 level (two-tailed t-test) compared tumour, liver and brain ganglioside content in untreated
and  NB-DNJ-treated mice. NB-DNJ significantly reduced the
total ganglioside content of both the EPEN and CT-2A tumours
grown either s.c. or i.c. (Table 1). Ganglioside concentration in
the NB-DNJ-treated EPEN and CT-2A tumours grown s.c. was
reduced by 56% and 39%, respectively. Ganglioside concentra-
tion of the treated tumours grown i.c. was reduced by 49% and
50%, respectively. The reduction in ganglioside content was
observed for gangliosides containing both NeuAc and NeuGc
sialic acids. In general, NB-DNJ treatment caused a greater reduc-
tion in NeuGc-containing gangliosides relative to NeuAc-
containing gangliosides (Table 1). NB-DNJ also significantly
reduced total liver ganglioside content by 74% (Table 1).
Although total brain ganglioside concentration (mg sialic acid
100 mg dry weight–1 ± SEM) was about 11% lower in the NB-
DNJ-treated mice (454 ± 19, n = 3) than in the untreated control
mice (508 ± 10, n = 3), the difference was not statistically signifi-
cant (determined by the two-tailed t-test). GSLs within the brain
have a relatively slow turnover, rendering brain ganglioside
biosynthesis less susceptible to inhibition by NB-DNJ. These
findings suggest that NB-DNJ inhibition of ganglioside synthesis
is greater in the more metabolically active tissues than in the less
metabolically active tissues. 
Influence of NB-DNJ on tumour, liver and brain
ganglioside distribution 
The HPTLC distribution of gangliosides in the untreated EPEN
and CT-2A tumours grown s.c. or i.c. was similar to the distribu-
tion that we reported previously for these tumours (Seyfried 
et al, 1987; Cotterchio and Seyfried, 1993; El-Abbadi and
Seyfried, 1994). GM3 is the only ganglioside synthesized by
cultured EPEN cells, while gangliosides in the ‘a’ metabolic
pathway (GM3, GM2, GM1, GD1a) are the major gangliosides
synthesized by cultured CT-2A cells. Most other gangliosides in
the tumours are derived from tumour-infiltrating host cells or from
the serum (Seyfried et al, 1996; Ecsedy et al, 1998; Seyfried et al,
1998). The significant reduction in total ganglioside content in
the NB-DNJ-treated tumours (Table 1) was associated with a
noticeable shift in ganglioside distribution from the structurally
simple (GM3) to the structurally complex gangliosides (GD1a,
GT1b) (Figure 5). NB-DNJ treatment had no significant effect
on the distribution of brain or liver gangliosides (data not
shown). 
NB-DNJ content in serum and tissue of healthy mice 
To determine the tissue bioavailability, NB-DNJ levels were
measured in the brain, liver and serum of healthy B6 mice after 9
days of treatment at 2400 mg kg–1 d–1. The concentration of NB-
DNJ in the serum was 58 mM ± 4.4 (n = 3), an amount consistent
with steady-state serum levels previously reported (Platt et al,
1997b). NB-DNJ concentration in the liver was 4.6 ± 0.7 mg g–1
wet weight (n = 3), which was more than 10-fold higher than that
in the brain (0.3 ± 0.1 mg g–1 wet weight, n = 3). These findings
suggest that NB-DNJ uptake is greater in the more metabolically
active liver tissue than in the less metabolically active brain tissue
or that the blood-brain barrier restricts brain uptake. 
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Figure 5 High-performance thin-layer chromatogram showing the effects of
NB-DNJ treatment on EPEN (A) and CT-2A (B) tumour ganglioside
distribution. Approximately 2 mg of ganglioside sialic acid were spotted for
each sample. The plate was developed by one ascending elution with
chloroform:methanol:water (50:45:10, v/v/v) that contained 0.02%
CaCl22H2O. The bands were visualized by resorcinol spray (50). In (A) and
(B), lanes 1, ganglioside standards; lanes 2, adult mouse brain gangliosides;
lanes 3, control s.c. tumours; lanes 4, NB-DNJ-treated s.c. tumours; lanes 5,
control i.c. tumours; lanes 6, NB-DNJ-treated i.c. tumours
Table 1 Influence of NB-DNJ on ganglioside content in experimental mouse brain tumours and liver 
Ganglioside neuraminic acid content, mg 100 mg–1 dry weight 
Tissue Growth  Treatment Na Total NeuAcb NeuGc % NeuGc 
Environment
EPEN 
SCc Control 4 44.4 ± 5.2 38.1 ± 5.1 6.3 ± 1.1 14 
NB-DNJ 6 19.5 ± 2.0** 16.0 ± 1.6**  3.5 ± 0.5* 18 
IC Control 3 68.5 ± 0.6 60.5 ± 1.2 8.0 ± 0.9 12 
NB-DNJ 3 35.0 ± 3.5** 32.6 ± 2.9**  2.4 ± 0.5* 7 
CT-2A 
SC Control 6 62.2 ± 5.9 39.2 ± 3.8 23.1 ± 4.0 37 
NB-DNJ 6 37.8 ± 4.0* 28.7 ± 2.7  9.0 ± 1.3* 24 
IC Control 6 61.6 ± 3.3 43.1 ± 3.7 18.5 ± 1.3 30 
NB-DNJ 6 30.9 ± 2.9** 25.2 ± 2.7*  5.7 ± 0.9** 18 
Liver 
Control 3 30.5 ± 2.9 1.95 ± 0.2  28.6 ± 2.7 94 
NB-DNJ 4 11.9 ± 1.2** 2.7 ± 0.2  9.2 ± 1.2** 77 
aN, number of independent tumour or liver samples studied. Values are expressed as means ± the SEM. bNeuAc, N-acetylneuraminic acid;
NeuGc, N-glycolylneuraminic acid. cIC, intracerebral; SC, subcutaneous. Asterisks indicate that the control and treated tissue differ at the 
P < 0.01 (*) and P < 0.001 (**) levels as determined by the two-tailed t test. Influence of N B-DNJ on EPEN and CT-2A on
histological features 
To ascertain whether a reduction in growth and ganglioside content
may affect tissue morphology, we examined NB-DNJ-treated
EPEN and CT-2A tumours using H&E staining. NB-DNJ treatment
had no significant effect on the histological morphology of the
EPEN tumour, which appeared as previously described (Seyfried 
et al, 1987). In parallel, NB-DNJ treatment had no significant effect
on the morphology of the CT-2A tumour (Figure 6). The amount of
necrosis or pyknosis was not noticeably different between the
control and NB-DNJ-treated EPEN or CT-2A tumours. 
Side effects of NB-DNJ treatment 
NB-DNJ was not overtly toxic as none of the treated mice died
during the experiment. After the third day of treatment, mice
receiving  NB-DNJ had a hunched stature and dull coat in compar-
ison to untreated control mice. The final mouse body weights were
13% lower on average in the NB-DNJ-treated groups, compared
to the control groups. The weight loss may be associated with
digestive problems since, upon dissection, the large intestines of
treated mice appeared distended by the presence of gas pockets.
NB-DNJ treatment did not affect brain dry weight, but reduced
spleen dry weight by 61%, as previously reported (Platt 
et al, 1997b; Andersson et al, 2000). Overall, the animals tolerated
N B-DNJ in their diet and were not seriously compromised by its
administration over the short treatment period. 
DISCUSSION 
Our data show that the small imino sugar, NB-DNJ, significantly
inhibited the growth rate and the ganglioside content of 2 different
experimental mouse brain tumours, the EPEN and the CT-2A. The
reduction of ganglioside content in the i.c.-grown tumours and the
detection of NB-DNJ in the brain tissue of normal mice suggests
that  NB-DNJ passes the blood–brain barrier, consistent with
previous studies (Platt et al, 1997a; Jeyakumar et al, 1999;
Andersson et al, 2000). In contrast to most known chemothera-
peutic molecules, NB-DNJ was non-cytotoxic and was generally
well tolerated by the B6 mouse host. Since gangliosides modulate
the activities of multiple cell surface receptors and adhesion mole-
cules that participate in cell proliferation, migration, and angio-
genesis (Hakomori, 1996; Alessandri et al, 1997), it is possible
that the NB-DNJ-linked inhibition of ganglioside biosynthesis is
responsible for the reduced tumour growth. We do not exclude the
possibility that NB-DNJ may also reduce tumour growth through
effects on N-linked glycosylation or on caloric intake (Weindruch
and Walford, 1988; Karlsson et al, 1993; Platt and Butters, 1995).
It is unlikely that NB-DNJ reduces brain tumour growth through
an effect on apoptosis because no noticeable differences were seen
between the control and the NB-DNJ-treated tumours for the
number of dead cells in vitro or for cell pyknosis or tissue necrosis
in vivo. Additional studies will be needed to determine the
mechanisms by which NB-DNJ inhibits brain tumour growth
and whether reduced tumour growth and ganglioside content are
correlated with NB-DNJ dosage. 
We found that NB-DNJ reduced the content of NeuGc-containing
gangliosides to a greater extent than that of NeuAc-containing
gangliosides in the i.c.-grown brain tumours. We previously
showed that most NeuGc-containing gangliosides present in
mouse brain tumours and in human glioma xenografts are derived
from tumour-associated host cells (macrophages) and from the
mouse serum (Ecsedy et al, 1998, 1999; Seyfried et al, 1998).
Since most NeuGc-containing gangliosides in mouse serum are
synthesized in the liver (Cotterchio and Seyfried, 1994), we
suggest that the marked reduction of NeuG-containing ganglio-
sides in the i.c.-grown brain tumours results in large part from 
the NB-DNJ-induced inhibition of ganglioside biosynthesis in 
the liver. It is not yet known if NB-DNJ might also reduce 
tumour NeuGc content through an effect on tumour-associated
macrophages. 
We recently showed that gene-linked changes in ganglioside
distribution could influence angiogenesis in the EPEN tumour
(Manfredi et al, 1999). Specifically, the neosynthesis of complex
gangliosides (GM2, GM1, and GD1a) with a concurrent decrease
in GM3 enhanced angiogenesis. These shifts in ganglioside distri-
bution, however, were not associated with changes in total cellular
ganglioside content. Although we found similar ganglioside shifts
in the NB-DNJ-treated tumours, these shifts were associated with
blocked ganglioside synthesis and significant reductions in total
ganglioside content. Further studies are needed to determine if the
effects of NB-DNJ on tumour ganglioside distribution also influ-
ence angiogenesis. 
The NB-DNJ-induced shift in tumour ganglioside distribution
from the more simple structures (GM3) to the more complex
gangliosides (GM1, GD1a) in the CT-2A tumour results from a
depletion of simple upstream metabolic precursors (glucosyl-
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Figure 6 Histological appearance of the CT-2A tumour grown
intracerebrally in control (A) and in NB-DNJ-treated (B) animals.
Magnification 3 200ceramide and lactosylceramide) together with the conversion of
already synthesized precursors to ganglioside end products
(GD1a). A similar phenomenon was described previously in
mouse embryos treated with N-butyldeoxygalactonojirimycin
(NB-DGJ), a structural analogue of NB-DNJ, and is consistent
with the substrate availability hypothesis of ganglioside biosyn-
thesis (Seyfried et al, 1994; Brigande et al, 1998). The shift in
ganglioside distribution in the EPEN tumour likely results from
the depletion of GM3 synthesis in the proliferating tumour cells.
Such a depletion will differentially magnify those gangliosides
(GM1, GD1a) in the less proliferative host cells e.g., macrophages.
Hence, NB-DNJ may influence tumour ganglioside composition
through effects on both the tumour cells and the host cells. 
Mammalian systems lack enzymes that metabolize the imino
sugars and, as a consequence, NB-DNJ is secreted intact via the
kidney (Platt and Butters, 1995, 1998). For this reason, secondary
metabolites do not complicate the biological effects of NB-DNJ.
The 58 mM steady-state serum level of NB-DNJ that we detected
in the B6 mice after 9 days of dietary administration (2400 mg
kg–1d–1) was similar to that found previously for inhibition of GSL
biosynthesis in normal and pathological mouse tissues (Platt et al,
1997a, 1997b; Jeyakumar et al, 1999). In these previous studies,
NB-DNJ treatment caused extensive depletion of GSLs in the liver
and the lymphoid organs of healthy B6 mice and reduced the
concentration of ganglioside GM2 in the brains of Tay-Sachs and
Sandhoff disease. In phase I and phase II clinical trials, NB-DNJ
effectively reduced glucocerebroside storage in patients with
Gaucher’s disease, but did not slow the progression of HIV infec-
tion (Fischl et al, 1994; Cox et al, 2000). Osmotic diarrhoea was
the major side effect reported in patients treated with NB-DNJ, and
was apparently caused by the competitive inhibition of the
intestinal disaccharidases, sucrase and isomaltase (Fischl et al,
1994; Platt et al, 1997b; Anderson et al, 2000). It is possible that
the intestinal gas pockets in our treated mice also relate to the NB-
DNJ-induced inhibition of digestive enzymes. Modification of
NB-DNJ dosage and carbohydrate intake may reduce GI tract
distress. In summary, our preclinical findings demonstrate for the
first time that NB-DNJ may be an effective, orally administered
chemotherapy for human brain tumours. 
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